Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Takeda Pharmaceutical CO Ltd (TAK)

Takeda Pharmaceutical CO Ltd (TAK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 50,759,276
  • Shares Outstanding, K 3,152,750
  • Annual Sales, $ 30,279 M
  • Annual Income, $ 407,020 K
  • 60-Month Beta 0.96
  • Price/Sales 1.73
  • Price/Cash Flow 4.79
  • Price/Book 1.20
Trade TAK with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.59
  • Growth Rate Est. (year over year) +169,222.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.09 +0.06%
on 10/28/20
18.45 -12.74%
on 09/29/20
-2.89 (-15.22%)
since 09/28/20
3-Month
16.09 +0.06%
on 10/28/20
19.67 -18.15%
on 08/24/20
-1.77 (-9.90%)
since 07/28/20
52-Week
12.43 +29.53%
on 03/18/20
20.92 -23.06%
on 11/19/19
-1.50 (-8.52%)
since 10/28/19

Most Recent Stories

More News
Moderna Partners with Takeda and the Government of Japan to Supply 50 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273) to Japan

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today confirmed that...

MRNA : 65.74 (-6.98%)
TAK : 16.10 (-2.72%)
Moderna May Supply 40M Coronavirus Vaccine Doses to Japan

Moderna (MRNA) is negotiating a deal with Japanese authorities for supply of its coronavirus vaccine in Japan, following a potential approval.

JNJ : 138.36 (-3.35%)
MRNA : 65.74 (-6.98%)
BNTX : 77.54 (-7.64%)
TAK : 16.10 (-2.72%)
Moderna Confirms Discussions with the Ministry of Health, Labour and Welfare to Supply Japan with 40 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today confirmed that...

MRNA : 65.74 (-6.98%)
TAK : 16.10 (-2.72%)
Novavax's (NVAX) Earnings Beat in Q2, Sales Lag Estimates

Novavax's (NVAX) loss narrows for the second quarter of 2020 but revenues miss the mark.

SNY : 46.14 (-2.66%)
NVAX : 81.33 (-9.22%)
EBS : 91.27 (-3.81%)
TAK : 16.10 (-2.72%)
Members Of The COVID R&D Alliance And Quantum Leap Healthcare Collaborative Enroll First Patients In I-SPY COVID Trial

, /PRNewswire/ -- Today, members of the COVID R&D Alliance AbbVie, Inc. (NYSE: ABBV), Amgen Inc. (NASDAQ: AMGN), and Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) announced the first patients enrolled in...

ABBV : 80.49 (-2.68%)
AMGN : 216.38 (-3.17%)
TAK : 16.10 (-2.72%)
Research Uncovers New Role Psychedelics Could Play in Therapy

, /PRNewswire/ -- The pharmaceutical industry develops drugs to diagnose, cure, treat or prevent diseases and it operates in one of the most diverse and complex markets. The pharmaceutical market is also...

TKPYY : 16.5900 (-0.90%)
MYCOF : 0.1465 (-4.68%)
MYCO.CN : 0.200 (-6.98%)
TAK : 16.10 (-2.72%)
TEVA : 8.76 (+0.23%)
MRNS : 13.16 (-2.05%)
SUPN : 17.70 (-6.05%)
Karyopharm's Xpovio Gets FDA Accelerated Approval for DLBCL

Karyopharm (KPTI) gets FDA approval for label expansion of its marketed drug, Xpovio, in relapsed or refractory diffuse large B-cell lymphoma.

AZN : 50.98 (-2.86%)
RHHBY : 40.0900 (-2.72%)
KPTI : 15.48 (-5.84%)
TAK : 16.10 (-2.72%)
Psychedelic Medicine and the Future of Mental Health Care Looks Promising

, /PRNewswire/ -- After decades of having a bad rep, psychedelics are making their way back into the medical world and are being touted for For years, Big Pharma companies (NYSE:PFE), (NYSE:TAK),(NYSE:TEVA)...

TKPYY : 16.5900 (-0.90%)
TAK : 16.10 (-2.72%)
ABBV : 80.49 (-2.68%)
TEVA : 8.76 (+0.23%)
PFE : 35.45 (-5.29%)
MMEDF : 0.8000 (-8.05%)
Myovant Eyes Relugolix Combo Approval for Uterine Fibroids

Myovant (MYOV) submits a regulatory application with the FDA seeking approval for oral relugolix combination regimen as a treatment for heavy menstrual bleeding associated with uterine fibroids.

JNJ : 138.36 (-3.35%)
ABBV : 80.49 (-2.68%)
MYOV : 14.65 (-4.62%)
TAK : 16.10 (-2.72%)
Protalix Submits BLA for Fabry Disease Candidate PRX-102

Protalix (PLX) announces submission of regulatory application seeking approval for its lead pipeline candidate, pegunigalsidase alfa, for Fabry disease.

SNY : 46.14 (-2.66%)
PLX : 3.55 (+0.57%)
AGEN : 3.69 (-3.91%)
TAK : 16.10 (-2.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strongest short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide...

See More

Key Turning Points

2nd Resistance Point 16.48
1st Resistance Point 16.29
Last Price 16.10
1st Support Level 16.00
2nd Support Level 15.90

See More

52-Week High 20.92
Fibonacci 61.8% 17.68
Fibonacci 50% 16.68
Last Price 16.10
Fibonacci 38.2% 15.68
52-Week Low 12.43

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar